New combo therapy tested to control spreading prostate cancer

This study tested a combination treatment for men newly diagnosed with prostate cancer that had spread to a few other sites in the body. The goal was to see if adding an immunotherapy drug (pembrolizumab), with or without an immune-boosting injection (SD-101), to standard radiation and hormone therapy could better control the cancer. Researchers measured safety and whether the treatment could keep prostate-specific antigen (PSA) levels low after hormone therapy was paused.